Mital Jhaveri: The Promise of Factor XI Inhibitors in Chronic Kidney Disease
Mital Jhaveri, Clinical Anticoagulation, Heart Failure Pharmacist at NYC HHC Queens Hospital Center, shared on LinkedIn about a recent article by Daniel Steiner et al, published in KIREPORTS, adding:
”Factor XI Inhibitors and Kidney Disease: A Game-Changer for a Forgotten Population?
One of the most underappreciated aspects of the FXI inhibitor story isn’t atrial fibrillation or VTE – it’s kidney disease.
The challenge we face includes:
- Patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are at high risk for both thrombosis and bleeding.
- Most direct oral anticoagulants (DOACs) have significant renal clearance, making them unsafe or contraindicated in severe CKD.
- Warfarin is notoriously difficult to manage in this population.
- Clinically relevant bleeding in anticoagulated dialysis patients can exceed 30%.
This situation leaves us hesitant to treat patients who need anticoagulation the most.
Factor XI inhibitors offer a different approach:
- Many FXI inhibitors have minimal to no renal clearance.
- FXI plays a greater role in pathological thrombosis than in normal hemostasis, making it safer for fragile patients.
- FXI is activated by artificial surfaces such as dialysis circuits and catheters, making it a mechanistically ideal target.
Phase II trials are already showing promise:
- The CONVERT trial with osocimab in hemodialysis showed no increase in bleeding compared to placebo.
- The RE-THINc ESRD trial with fesomersen was well-tolerated, with pharmacokinetics unchanged before or after dialysis.
- The EMERALD trial with FXI-ASO in ESRD demonstrated reduced FXI activity without a major increase in bleeding.
Phase III (LILAC-TIMI 76) is now enrolling ESKD patients.
For the nephrology and hematology community, this may represent the most clinically impactful application of FXI inhibition yet.”
Title: A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis
Authors: Daniel Steiner, Daniel Kraemmer, Stephan Nopp, Oliver Königsbrügge, Cihan Ay
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 12:47Louise St. Germain Bannon: Turning Thrombosis Awareness into Stroke Prevention
-
Oct 30, 2026, 12:36Aryabhatta Sadhu: Sickle Cell Crisis Recognising When Treatment Must Change
-
Oct 30, 2026, 12:22Fabrice Cognasse: The Future of Blood Banks From Transfusion Support to Precision Medicine
-
Oct 30, 2026, 12:09Carmelo Gurnari: Clonal Dynamics in the Bone Marrow During Sepsis and Emergency Haematopoiesis
-
Oct 30, 2026, 11:49Advancing Global Care for Hemophilia and Bleeding Disorders – World Federation of Hemophilia
-
Oct 30, 2026, 05:18Flora Peyvandi: Molecular and Lab Markers Linked to Bleeding Severity in Factor VII Deficiency
-
Oct 30, 2026, 05:11Rana Al-Hrout: Exploring Approach to Macrocytic Anemia
-
Oct 30, 2026, 04:22Francisco Chacón-Lozsán: Acute Pulmonary Embolism in 2026 – Blood Pressure Is Not the Same as Perfusion
-
Oct 30, 2026, 04:15Samin Mohsenian: Launching the PRO-RBDD-FX Registry for Rare Coagulation Factor X Deficiency